+

WO2013048130A3 - Molécule de liaison pour neutraliser un virus de la rage - Google Patents

Molécule de liaison pour neutraliser un virus de la rage Download PDF

Info

Publication number
WO2013048130A3
WO2013048130A3 PCT/KR2012/007795 KR2012007795W WO2013048130A3 WO 2013048130 A3 WO2013048130 A3 WO 2013048130A3 KR 2012007795 W KR2012007795 W KR 2012007795W WO 2013048130 A3 WO2013048130 A3 WO 2013048130A3
Authority
WO
WIPO (PCT)
Prior art keywords
rabies virus
binding molecule
neutralizing
neutralizing rabies
species
Prior art date
Application number
PCT/KR2012/007795
Other languages
English (en)
Korean (ko)
Other versions
WO2013048130A2 (fr
Inventor
장신재
김판겸
김만수
박현진
Original Assignee
(주)셀트리온
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)셀트리온 filed Critical (주)셀트리온
Priority to CN201280047216.2A priority Critical patent/CN103998059B/zh
Publication of WO2013048130A2 publication Critical patent/WO2013048130A2/fr
Publication of WO2013048130A3 publication Critical patent/WO2013048130A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)

Abstract

La présente invention concerne une molécule de liaison conçue pour neutraliser un virus de la rage. De manière plus spécifique, la molécule de liaison selon l'invention permet de neutraliser le virus de la rage qui est dérivé d'espèces telles que les chauves-souris, les chiens, les vaches, les mangoustes, les mouffettes et les loups, et peut ainsi être utilisé pour traiter un patient qui a contracté le virus de la rage dérivé d'une grande variété d'espèces.
PCT/KR2012/007795 2011-09-30 2012-09-27 Molécule de liaison pour neutraliser un virus de la rage WO2013048130A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280047216.2A CN103998059B (zh) 2011-09-30 2012-09-27 用于中和狂犬病病毒的结合分子

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0099685 2011-09-30
KR20110099685 2011-09-30

Publications (2)

Publication Number Publication Date
WO2013048130A2 WO2013048130A2 (fr) 2013-04-04
WO2013048130A3 true WO2013048130A3 (fr) 2013-05-23

Family

ID=47996620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/007795 WO2013048130A2 (fr) 2011-09-30 2012-09-27 Molécule de liaison pour neutraliser un virus de la rage

Country Status (3)

Country Link
KR (1) KR101495019B1 (fr)
CN (1) CN103998059B (fr)
WO (1) WO2013048130A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101739313B1 (ko) * 2013-12-12 2017-05-24 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
CN107709360B (zh) * 2015-06-10 2021-10-19 赛特瑞恩股份有限公司 狂犬病毒g蛋白表位及与其特异性结合的中和狂犬病毒的结合分子
EP3873526B1 (fr) * 2018-11-02 2024-09-04 Zydus Lifesciences Limited Anticorps monoclonaux anti-rage et cocktail associés

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695757A (en) * 1993-05-26 1997-12-09 Thomas Jefferson University Methods for treating post-exposure rabies and anti-rabies compositions
US20060216300A1 (en) * 2003-06-13 2006-09-28 Thomas Jefferson University Recombinant antibodies and compositions and methods for making and using the same
US20070072177A1 (en) * 2004-05-27 2007-03-29 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
US20090041777A1 (en) * 2005-02-02 2009-02-12 Thomas Jr William D Human antibodies against rabies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748567B2 (en) * 2006-05-22 2014-06-10 Children's Medical Center Corporation Method for delivery across the blood brain barrier
CN101696242B (zh) * 2009-10-26 2011-12-28 中国人民解放军南京军区军事医学研究所 人源抗狂犬病毒中和抗体Fab及其制备方法和应用
CN101812130B (zh) * 2010-05-06 2012-07-04 中国疾病预防控制中心病毒病预防控制所 人源抗狂犬病毒糖蛋白中和性抗体(RVFab5)
CN102643343B (zh) * 2011-02-17 2015-03-25 长春百克生物科技股份公司 一种人源抗狂犬病毒糖蛋白基因工程抗体及其制备与应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695757A (en) * 1993-05-26 1997-12-09 Thomas Jefferson University Methods for treating post-exposure rabies and anti-rabies compositions
US20060216300A1 (en) * 2003-06-13 2006-09-28 Thomas Jefferson University Recombinant antibodies and compositions and methods for making and using the same
US20070072177A1 (en) * 2004-05-27 2007-03-29 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
US20090041777A1 (en) * 2005-02-02 2009-02-12 Thomas Jr William D Human antibodies against rabies and uses thereof

Also Published As

Publication number Publication date
KR20130036150A (ko) 2013-04-11
CN103998059A (zh) 2014-08-20
KR101495019B1 (ko) 2015-02-24
WO2013048130A2 (fr) 2013-04-04
CN103998059B (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
WO2013040492A3 (fr) Procédés permettant de traiter le virus de l'hépatite c (hcv)
CA2865594C (fr) Molecules de liaison humaines aptes a se lier a des virus de la grippe b et de neutraliser des virus de la grippe b, et leurs utilisations
WO2012109373A3 (fr) Traitement de l'arthrose et de la douleur
WO2014052836A3 (fr) Procédés et compositions de traitement d'une infection
WO2012129341A3 (fr) Détection d'une maladie chez les plantes
WO2012170807A3 (fr) Molécules de liaison anti-psl de pseudomonas et leurs utilisations
WO2013109974A3 (fr) Anticorps anti-cxcr3
WO2012135177A3 (fr) Procédés et compositions permettant d'obtenir une protéine il-10 de cytomégalovirus
WO2013120022A3 (fr) Traitement de l'hypoglycémie
ZA201404494B (en) Method for treating hepatitis c virus infection using quercetin-containing compositions
WO2010032011A8 (fr) Thérapie antifongique
WO2012017321A3 (fr) Traitement de la dyslipidémie
WO2013022550A3 (fr) Inhibiteurs à petites molécules des virus ébola et de la fièvre de lassa
WO2012162580A3 (fr) Composés antiviraux
LT2683245T (lt) Būdai ir kompozicijos, skirti depresijai gydyti panaudojant ciklobenzapriną
WO2010089554A8 (fr) Vaccin à base de peptides
WO2012162578A3 (fr) Composés antiviraux
WO2010098583A3 (fr) Nouveau procédé de préparation de composés de statine ou des sels de ceux-ci, et composés intermédiaires utilisés dans ce procédé
WO2013005042A3 (fr) Traitement anti-viral
WO2012048115A3 (fr) Polypeptides et leur utilisation dans le but de traiter et de circonscrire une infection par un virus respiratoire syncytial
WO2013048130A3 (fr) Molécule de liaison pour neutraliser un virus de la rage
WO2013152274A8 (fr) Immunogènes à échafaudage d'épitope contre le virusm respiratoire syncytial (rsv)
EA201491581A1 (ru) Везикулярные композиции
WO2012162471A3 (fr) Extrait végétal de pachycereus et ses procédés d'utilisation
ZA201307019B (en) Compositions for preventing and/or treating and infection by an hiv-1 virus

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12837417

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载